3M acquires Zargis's heart diagnostic tech
This article was originally published in Clinica
3M Health Care has acquired certain assets of Zargis Medical relating to its Cardioscan software, which helps identify and classify suspected heart murmurs. Financial terms of the deal were not disclosed. Specifically, the deal includes Cardioscan, which was cleared by the US FDA in 2004 and by Health Canada in January 2010 (www.clinica.co.uk, 11 January 2010), as well as Zargis's TeleSteth and StethAssist software. The former is an online tele-ausculation (listening with a stethoscope) product which allows healthcare professionals to share internal sounds with colleagues over the internet, while StethAssist is used with electronic stethoscopes to record and display these acoustic signals. 3M and Zargis already had a partnership in which the former's Littmann Model 3200 stethoscope was used in combination with the latter's software.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.